JACOBSON PHARMA (02633) announces its interim performance with a net profit attributable to shareholders of 142 million Hong Kong dollars, representing a year-on-year increase of 1.24%.

Jacobson Pharma (02633) announced its mid-year performance for 2025. The group achieved a revenue of HK$767 million, a decrease of 5.36% compared to the same period last year. The net profit attributable to equity holders of the company was HK$142 million, an increase of 1.24% year-on-year. Basic earnings per share were 7.12 HK cents. The mid-year dividend per share was 4.25 HK cents.